Prescription Drug Supply Chain Pricing Transparency Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Prescription Drug Supply Chain Pricing Transparency Act (H.R. 7535) is a legislative proposal introduced in the 118th Congress aimed at increasing transparency within the prescription drug supply chain. Although the official summary and full text of the bill are not available, the title indicates the bill's focus on pricing transparency in the pharmaceutical supply chain. The bill was referred to the Subcommittee on Health but ultimately failed or expired without further legislative action.
H.R. 7535 sought to enhance transparency in prescription drug pricing within the supply chain but did not advance beyond referral to a subcommittee and expired without enactment.
- The bill addresses transparency in the pricing mechanisms of the prescription drug supply chain.
- It was introduced in the House of Representatives during the 118th Congress.
- The bill was referred to the Subcommittee on Health but did not progress further and expired.
['Patients and consumers seeking clearer information on prescription drug pricing.', 'Healthcare providers and pharmacies involved in the drug supply chain.', 'Regulatory agencies overseeing drug pricing and supply chain practices.']
['Lack of available full bill text limits understanding of specific provisions and enforcement mechanisms.', 'Implementation challenges related to data collection and reporting requirements could arise.', 'Potential costs associated with compliance for supply chain entities and administrative oversight.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and expired, indicating limited legislative momentum or prioritization during the session. The focus on drug pricing transparency aligns with ongoing policy discussions about prescription drug costs in the health policy area.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Increased transparency could influence pricing negotiations and market behavior among pharmaceutical supply chain participants.', 'Enhanced data availability might support regulatory oversight and policy development related to drug pricing.', 'Potential administrative burden on smaller supply chain entities due to reporting requirements.']
The absence of an official summary and full bill text limits detailed analysis of the bill's provisions and enforcement mechanisms. Transparency in drug pricing is a complex policy area requiring clear definitions and oversight structures to ensure effectiveness. Monitoring legislative progress and obtaining full text would be essential for comprehensive evaluation.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.